Please assess the completion status of the following clinical trial:

Trial Title: Phase III Tolerance and Efficacy Study of RSD1235 in Patients With Atrial Fibrillation

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: TRIPLE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* 18 years of age or older;~* Have an atrial arrhythmia with symptoms that has been sustained for greater than 3 hours and up to 45 days.~* Have adequate anticoagulant therapy.~Exclusion Criteria:~* Have a QRS \> 0.14 seconds unless patient has pacemaker or uncorrected QT \> 0.440 seconds as measured on a 12-lead ECG.~* Have serious diseases/illnesses that could interfere with the conduct or validity of the study or compromise patient safety.~* Have received intravenous Class I or Class III antiarrhythmic drugs or intravenous amiodarone within 24 hours prior to dosing.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- 1 (Type: EXPERIMENTAL): Atrial fibrillation (AF) duration of 3 hours to 7 days.
- 2 (Type: EXPERIMENTAL): AF duration of \>7 days to \<45 days

Based on this trial design, predict the completion outcome and termination type (if applicable).